Streck CE-Marked Kits Detect More than 450 β Lactamase Gene Targets
Streck’s new line of CE-marked antibiotic resistance monitoring and detection (ARM-D) kits are now available. The Streck ARM-D® Kits, ampC and β-Lactamase are multiplex real-time PCR reagents for the detection of more than 450 β lactamase gene targets. The kits are For Export Only. Not for sale in the U.S.
The Streck ARM-D Kits detect the presence of antibiotic resistance genes in bacteria that cause difficult-to-treat infections and that have the ability to spread quickly, especially in a hospital environment. The Streck ARM-D Kits can detect the presence of resistance mechanisms of current clinical importance, such as carbapenemases and extended spectrum β-Lactamases (ESBLs) and some emerging threats, such as the AmpC cephalosporinases. Current phenotypic methods may mischaracterize or fail to detect genetic mechanisms of antibiotic resistance. The Streck ARM-D Kits are a genotypic detection method that can be used to identify the most prevalent types of β-lactamase-based antibiotic resistance.
Streck developed the ARM-D Kits to provide laboratories with a comprehensive, cost-effective molecular method to detect the most clinically-important β-lactamases known to cause therapeutic failure. These kits can be used to complement standard susceptibility tests, improve surveillance and epidemiologic tracking, and also foodborne pathogen and waste water testing.
Tags: Extended-Spectrum Beta-Lactamase ESBL, Antibiotic Resistance
Date Published: February 7, 2017
Source article link: Streck » company contact details
Novodiag® Launched - New Diagnostic Solution for Infectious Diseases
FDA-Cleared Liofilchem MIC Test Strip (MTS™) Erythromycin (E)
LiDia® BSI Test: Detection of Pathogens in Clinical Whole Blood Samples
BIVDA Calls for Funding to Implement Rapid Diagnostics
Study Outlines ‘Perfect Storm’ that Led to Antibiotic Resistance Epidemic